This is a working overview of Reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
=== Self-assembly by molecular interactions === Nanoparticles have the ability to assemble chemically through covalent or noncovalent interactions with their capping ligand. The terminal functional group(s) on the particle are known as capping ligands. As these ligands tend to be complex and sophisticated, self-assembly can provide a simpler pathway for nanoparticle organization by synthesizing efficient functional groups. For instance, DNA oligomers have been a key ligand for nanoparticle building blocks to be self-assembling via sequence-based specific organization. However, to deliver precise and scalable (programmable) assembly for a desired structure, a careful positioning of ligand molecules onto the nanoparticle counterpart should be required at the building block (precursor) level, such as direction, geometry, morphology, affinity, etc. The successful design of ligand-building block units can play an essential role in manufacturing a wide-range of new nano systems, such as nanosensor systems, nanomachines/nanobots, nanocomputers, and many more uncharted systems.
In steady state, Grx2 forms dimers to coordinate iron-sulfur clusters, which in turn inactivate Grx2's activity by sequestering the active-site cysteines. During oxidative stress, the dimers separate into iron-free active monomers, which restore Grx2's activity.
== Development == The mod was announced on March 6, 2014, by Coburn on Mod DB, citing the original Half-Life game and user-created mods as a reason to "give back to the community." Coburn stated that the mod was his "first real modding effort," creating a small campaign before expanding it during his spare time. The development took five years to complete before releasing on August 10. During the development, his child was born with a heart complication and required surgery at the Royal Hospital for Children, Glasgow and recovered. After the mod was complete, he requested all fans who wanted to donate to the hospital. The mod uses voice lines from the original Half-Life, as well as Half-Life: Opposing Force, Half-Life: Blue Shift, Half-Life: Decay, and Half-Life 2: Episode Two. On August 12, 2021, a team of developers announced a remake in Black Mesa called Black Mesa: Candidate Twelve after half a year in production. However this was confirmed to be on a hiatus in 2025 as they moved onto other projects.
The duration of estradiol esters in oil solution by intramuscular injection is dose-dependent. With estradiol valerate, it is reported that a dose of 5 mg has a duration of 7 to 8 days, 10 mg a duration of 10 to 14 days, 40 mg a duration of 2 to 3 weeks, and 100 mg a duration of 3 to 4 weeks. High doses of estradiol valerate, such as 40 mg per week, can achieve pregnancy levels of estradiol. A study of pseudopregnancy with intramuscular injections of 40 mg/week estradiol valerate and 250 mg/week hydroxyprogesterone caproate observed estradiol levels of about 2,500 to 3,000 pg/mL.
==== 17OHP subpathway ==== The first step of this pathway is the 5α-reduction of 17OHP to 5α-pregnan-17α-ol-3,20-dione (referred to as 17OHDHP or 17α-hydroxy-dihydroprogesterone). The reaction is catalyzed by SRD5A1. 17OHDHP is then converted to 5α-pregnane-3α,17α-diol-20-one (5α-Pdiol) via 3α-reduction by a 3α-hydroxysteroid dehydrogenase isozyme (AKR1C2 and AKR1C4) or HSD17B6, that also has 3α-reduction activity. The pathway then proceeds from 5α-Pdiol the same way as the pathway that starts from P4, i.e. 5α-Pdiol → AST → 3α-diol → DHT. The pathway can be summarized as: 17OHP → 17OHDHP → 5α-Pdiol → AST → 3α-diol → DHT.
Sources: en.wikipedia.org
Some patients who have their blood pressure measured in a clinical setting have higher readings than they do when measured in a home setting. This is apparently a result of patients feeling more relaxed when they are at home. The phenomenon is sometimes called white coat hypertension, in reference to the traditional white coats worn in a clinical setting, though the coats themselves may have nothing to do with the elevated readings.
== General biochemistry concepts == Major categories of bio-compounds: Carbohydrates : sugar – disaccharide – polysaccharide – starch – glycogen Lipids : fatty acid – fats – essential oils – oils – waxes – cholesterol Nucleic acids : DNA – RNA – mRNA – tRNA – rRNA – codon – adenosine – cytosine – guanine – thymine – uracil Proteins : amino acid – glycine – arginine – lysine peptide – primary structure – secondary structure – tertiary structure – conformation – protein folding Chemical properties: molecular bond – covalent bond – ionic bond – hydrogen bond – ester – ethyl molecular charge – hydrophilic – hydrophobic – polar pH – acid – alkaline – base oxidation – reduction – hydrolysis Structural compounds: In cells: flagellin – peptidoglycan – myelin – actin – myosin In animals: chitin – keratin – collagen – silk In plants: cellulose – lignin – cell wall Enzymes and enzyme activity: enzyme kinetics – enzyme inhibition proteolysis – ubiquitin – proteasome kinase – dehydrogenase Membranes : fluid mosaic model – diffusion – osmosis phospholipids – glycolipid – glycocalyx – antigen – isoprene ion channel – proton pump – electron transport – ion gradient – antiporter – symporter – quinone – riboflavin Biomolecule (list) Biomolecular engineering Biomolecular structure Multi-state modeling of biomolecules Energy pathways : pigments : chlorophyll – carotenoids – xanthophyll – cytochrome – phycobilin – bacteriorhodopsin – hemoglobin – myoglobin – absorption spectrum – action spectrum – fluorescence Photosynthesis : light reaction – dark reaction Fermentation : Acetyl-CoA – lactic acid Cellular respiration : Adenosine triphosphate (ATP) – NADH – pyruvate – oxalate – citrate Chemosynthesis Regulation hormones : auxin signal transduction – growth factor – transcription factor – protein kinase – SH3 domain Malfunctions : tumor – oncogene – tumor suppressor gene Receptors : Integrin – transmembrane receptor – ion channel Techniques : electrophoresis – chromatography – mass spectrometry – x-ray diffraction – Southern blot – fractionation – Gram stain – Surface Plasmon Resonance – Microscale Thermophoresis
Immediate-release oxycodone (OxyFast, OxyIR, OxyNorm, Roxicodone, Shortec) Controlled-release oxycodone (OxyContin, Xtampza ER, Oxypro) – 10–12 hour duration Oxycodone tamper-resistant (OxyContin OTR) Immediate-release oxycodone with paracetamol (acetaminophen) (Percocet, Endocet, Roxicet, Tylox) Immediate-release oxycodone with aspirin (Endodan, Oxycodan, Percodan, Roxiprin) Immediate-release oxycodone with ibuprofen (Combunox) Controlled-release oxycodone with naloxone (Targin, Targiniq, Targinact) – 10–12 hour duration Controlled-release oxycodone with naltrexone (Troxyca) – 10–12 hour duration
Their relationship is strained as Cain urges a firmer stance against the refugees and threats in town and threatens to take control from Jenna. The Homestead comes under direct attack and key residents are killed. Cain agitates the Homesteaders to turn against Jeff as Jeff questions Jenna's leadership. A radical religious sect in town led by a man called Father Burnham, who has a few congregants among the Homesteaders, claims Ian Ross promised their church a quarter of the Homestead's supplies in the event of a collapse. He allies with Masterson and Raven Rock to agitate outsiders against the Homesteaders. The city government engages in skirmishes with the Homesteaders to test their defenses. Tara becomes disillusioned with Jenna also and she and Jeff consider whether to try to take over the Homestead. They reach a breaking point after their son is injured by a snakebite. Masterson and Bing invite Jeff to join their side. Burnham tries to convince members of his congregation who are Homesteaders to turn against Jenna. As threats grow, the Homesteaders wrestle with moral choices as they try to prepare for an inevitable attack by Raven Rock. They try to recruit people from town to fight in exchange for food. Abe clashes with Jeff, who is trying to determine how best to lead his family. As the Homesteaders anticipate the impending attack, various members must decide whose side they are on and what they will do.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.